New York State Common Retirement Fund’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $29.6M | Buy |
175,474
+700
| +0.4% | +$104K | 0.04% | 342 |
|
|
2026
Q1 | $23M | Hold |
174,774
| – | – | 0.03% | 385 |
|
|
2025
Q4 | $24.8M | Sell |
174,774
-800
| -0.5% | -$116K | 0.03% | 354 |
|
|
2025
Q3 | $24.6M | Buy |
175,574
+800
| +0.5% | +$108K | 0.03% | 380 |
|
|
2025
Q2 | $22M | Hold |
174,774
| – | – | 0.03% | 414 |
|
|
2025
Q1 | $19.3M | Sell |
174,774
-3,000
| -2% | -$380K | 0.03% | 431 |
|
|
2024
Q4 | $24.3M | Sell |
177,774
-2,000
| -1% | -$247K | 0.03% | 374 |
|
|
2024
Q3 | $20.7M | Sell |
179,774
-28,633
| -14% | -$3.93M | 0.03% | 479 |
|
|
2024
Q2 | $28.7M | Buy |
208,407
+2,039
| +1% | +$280K | 0.04% | 363 |
|
|
2024
Q1 | $28.5M | Sell |
206,368
-8,028
| -4% | -$1.1M | 0.04% | 391 |
|
|
2023
Q4 | $28.2M | Sell |
214,396
-29,456
| -12% | -$3.39M | 0.04% | 395 |
|
|
2023
Q3 | $27.4M | Buy |
243,852
+30,539
| +14% | +$3.22M | 0.04% | 385 |
|
|
2023
Q2 | $20.1M | Buy |
213,313
+8,844
| +4% | +$864K | 0.03% | 559 |
|
|
2023
Q1 | $20.7M | Sell |
204,469
-25,770
| -11% | -$2.68M | 0.03% | 549 |
|
|
2022
Q4 | $27.5M | Sell |
230,239
-43,761
| -16% | -$5.13M | 0.04% | 424 |
|
|
2022
Q3 | $29.1M | Buy |
274,000
+23,213
| +9% | +$2.36M | 0.04% | 385 |
|
|
2022
Q2 | $24.4M | Buy |
250,787
+6,251
| +3% | +$577K | 0.03% | 466 |
|
|
2022
Q1 | $22.9M | Buy |
244,536
+31,479
| +15% | +$2.67M | 0.02% | 567 |
|
|
2021
Q4 | $18.1M | Buy |
213,057
+1,977
| +0.9% | +$182K | 0.02% | 714 |
|
|
2021
Q3 | $20.2M | Sell |
211,080
-39,506
| -16% | -$3.73M | 0.02% | 666 |
|
|
2021
Q2 | $24.4M | Sell |
250,586
-2,411
| -1% | -$231K | 0.03% | 596 |
|
|
2021
Q1 | $24.6M | Sell |
252,997
-10,309
| -4% | -$1.08M | 0.03% | 569 |
|
|
2020
Q4 | $25.2M | Buy |
263,306
+38,035
| +17% | +$3.67M | 0.03% | 550 |
|
|
2020
Q3 | $21.7M | Buy |
225,271
+43,563
| +24% | +$5.04M | 0.03% | 557 |
|
|
2020
Q2 | $22.2M | Sell |
181,708
-9,587
| -5% | -$1.06M | 0.03% | 544 |
|
|
2020
Q1 | $16.6M | Sell |
191,295
-755
| -0.4% | -$73.9K | 0.02% | 586 |
|
|
2019
Q4 | $20.6M | Sell |
192,050
-61,447
| -24% | -$6.43M | 0.02% | 637 |
|
|
2019
Q3 | $22.8M | Buy |
253,497
+1,290
| +0.5% | +$121K | 0.03% | 577 |
|
|
2019
Q2 | $21.3M | Buy |
252,207
+8,222
| +3% | +$675K | 0.03% | 628 |
|
|
2019
Q1 | $21.5M | Sell |
243,985
-17,929
| -7% | -$1.5M | 0.03% | 616 |
|
|
2018
Q4 | $18.7M | Sell |
261,914
-12,830
| -5% | -$1.23M | 0.03% | 614 |
|
|
2018
Q3 | $33.8M | Sell |
274,744
-55
| -0% | -$6.24K | 0.04% | 445 |
|
|
2018
Q2 | $27M | Sell |
274,799
-18,175
| -6% | -$1.63M | 0.03% | 541 |
|
|
2018
Q1 | $24.3M | Sell |
292,974
-1,010
| -0.3% | -$85.3K | 0.03% | 580 |
|
|
2017
Q4 | $22.8M | Buy |
293,984
+33,688
| +13% | +$2.3M | 0.03% | 620 |
|
|
2017
Q3 | $16M | Buy |
260,296
+4,895
| +2% | +$258K | 0.02% | 748 |
|
|
2017
Q2 | $11.7M | Buy |
255,401
+65,005
| +34% | +$3.15M | 0.02% | 897 |
|
|
2017
Q1 | $8.24M | Buy |
190,396
+4,996
| +3% | +$214K | 0.01% | 1031 |
|
|
2016
Q4 | $7.17M | Sell |
185,400
-21,695
| -10% | -$982K | 0.01% | 1086 |
|
|
2016
Q3 | $10.5M | Buy |
207,095
+14,450
| +8% | +$720K | 0.02% | 901 |
|
|
2016
Q2 | $8.76M | Buy |
192,645
+94,778
| +97% | +$4.36M | 0.01% | 993 |
|
|
2016
Q1 | $3.87M | Sell |
97,867
-6,559
| -6% | -$260K | 0.01% | 1315 |
|
|
2015
Q4 | $5.91M | Sell |
104,426
-549
| -0.5% | -$27.9K | 0.01% | 1144 |
|
|
2015
Q3 | $4.18M | Sell |
104,975
-2,723
| -3% | -$132K | 0.01% | 1288 |
|
|
2015
Q2 | $5.14M | Buy |
107,698
+101,238
| +1,567% | +$4.29M | 0.01% | 1336 |
|
|
2015
Q1 | $257K | Buy |
+6,460
| New | +$231K | ﹤0.01% | 2120 |
|
Other funds holding NBIX
New York State Common Retirement Fund's NBIX Position: Q2 2026 in Review
New York State Common Retirement Fund increased its Neurocrine Biosciences (NBIX) stake by 0.4% in Q2 2026, buying an estimated $104K and bringing the position to 175,474 shares worth $29.6M. The position accounts for 0.04% of the portfolio, ranked #342.
New York State Common Retirement Fund first reported a position in NBIX in Q1 2015 and has held it in 46 quarters since. The position peaked at $33.8M in Q3 2018. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- New York State Common Retirement Fund held 175,474 shares of Neurocrine Biosciences worth $29.6M as of Q2 2026.
- New York State Common Retirement Fund bought 700 Neurocrine Biosciences shares in Q2 2026, an estimated $104K.
- Neurocrine Biosciences made up 0.04% of New York State Common Retirement Fund's portfolio in Q2 2026, its #342 holding.
- New York State Common Retirement Fund first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 46 quarters since.
- New York State Common Retirement Fund's Neurocrine Biosciences position peaked at $33.8M in Q3 2018.
- 778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.